TENAX THERAPEUTICS, INC. (TENX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US88032L6056
TENAX THERAPEUTICS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -56.39 m USD |
| EBIT | -52.60 m USD |
| Net income | -52.60 m USD |
| Diluted EPS – continuing operations | -1.34 USD |
Full history since 1995, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About TENAX THERAPEUTICS, INC.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
More stocks
- Grong Sparebank (GRONG.OL)
- AB Science S.A (AB.PA)
- OZ VISION INC. (OZVN)
- GrowGeneration Corp. (GRWG)
- Kumho Electric (001210.KS)
- LIQUIDMETAL TECHNOLOGIES INC (LQMT)
- Logistic Properties of the Americas (LPA)
- First Hartford Corporation (FHRT)
- Meridian Holdings Inc./NV (MRDN)
- CSP INC /MA/ (CSPI)
- Proxene Tools Co., Ltd. (6904.TWO)
- SIEBERT FINANCIAL CORP (SIEB)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.